CARLEEN RUBEL: Open Payments
NPI 1114904380 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,233 in 72 payments from 24 companies in 2025. Trend: 2023 $676 · 2024 $773 · 2025 $1,233
Food & beverage: $1,233
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $312 |
| AstraZeneca Pharmaceuticals LP | 4 | $148 |
| Novo Nordisk Inc | 6 | $96 |
| PFIZER INC. | 5 | $95 |
| GlaxoSmithKline, LLC. | 5 | $94 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Alkermes, Inc. | 4 | $60 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 3 | $35 |
| Corium, LLC | 2 | $31 |
Products named: UBRELVY, AIRSUPRA, QULIPTA, Ozempic, TRELEGY ELLIPTA, CAPLYTA, LYBALVI, NURTEC ODT.
Industry payments across IN — which companies pay providers there.
